JP2018512443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512443A5 JP2018512443A5 JP2017562952A JP2017562952A JP2018512443A5 JP 2018512443 A5 JP2018512443 A5 JP 2018512443A5 JP 2017562952 A JP2017562952 A JP 2017562952A JP 2017562952 A JP2017562952 A JP 2017562952A JP 2018512443 A5 JP2018512443 A5 JP 2018512443A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr2
- cdr3
- cdr1
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 29
- 108090001123 antibodies Proteins 0.000 claims 29
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 210000004027 cells Anatomy 0.000 claims 5
- 230000003213 activating Effects 0.000 claims 3
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 102100016188 PVRIG Human genes 0.000 claims 1
- 101700053733 PVRIG Proteins 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 1
- 208000002918 Testicular Germ Cell Tumor Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000002519 immonomodulatory Effects 0.000 claims 1
- 230000003308 immunostimulating Effects 0.000 claims 1
- 230000001506 immunosuppresive Effects 0.000 claims 1
- 230000014828 interferon-gamma production Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000006439 lymphocytic leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000000770 pro-inflamatory Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000005161 thyroid carcinoma Diseases 0.000 claims 1
Claims (23)
- 癌の治療における使用のための、Ｔ細胞及び／又はＮＫ細胞を活性化するための抗ＰＶＲＩＧ抗体組成物であって、前記抗体がＰＶＲＩＧの少なくとも１つの免疫抑制効果に拮抗する、抗ＰＶＲＩＧ抗体組成物。
- 前記抗ＰＶＲＩＧ抗体が、
・図４１Ａ（ＣＨＡ．７．５０２）のｖｈＣＤＲ１（配列番号８２１）、ｖｈＣＤＲ２（配列番号８２２）、ｖｈＣＤＲ３（配列番号８２３）、ｖｌＣＤＲ１（配列番号８２５）、ｖｌＣＤＲ２（配列番号８２６）及びｖｌＣＤＲ３（配列番号８２７）の配列、
・図４１Ｂ（ＣＨＡ．７．５０３）のｖｈＣＤＲ１（配列番号８２９）、ｖｈＣＤＲ２（配列番号８３０）、ｖｈＣＤＲ３（配列番号８３１）、ｖｌＣＤＲ１（配列番号８３３）、ｖｌＣＤＲ２（配列番号８３４）及びｖｌＣＤＲ３（配列番号８３５）の配列、
・図４１Ｃ（ＣＨＡ．７．５０６）のｖｈＣＤＲ１（配列番号８３７）、ｖｈＣＤＲ２（配列番号８３８）、ｖｈＣＤＲ３（配列番号８３９）、ｖｌＣＤＲ１（配列番号８４１）、ｖｌＣＤＲ２（配列番号８４２）及びｖｌＣＤＲ３（配列番号８４３）の配列、
・図４１Ｄ（ＣＨＡ．７．５０８）のｖｈＣＤＲ１（配列番号８４５）、ｖｈＣＤＲ２（配列番号８４６）、ｖｈＣＤＲ３（配列番号８４７）、ｖｌＣＤＲ１（配列番号８４９）、ｖｌＣＤＲ２（配列番号８５０）及びｖｌＣＤＲ３（配列番号８５１）の配列、
・図４１Ｅ（ＣＨＡ．７．５１０）のｖｈＣＤＲ１（配列番号８５３）、ｖｈＣＤＲ２（配列番号８５４）、ｖｈＣＤＲ３（配列番号８５５）、ｖｌＣＤＲ１（配列番号８５７）、ｖｌＣＤＲ２（配列番号８５８）及びｖｌＣＤＲ３（配列番号８５９）の配列、
・図４１Ｆ（ＣＨＡ．７．５１２）のｖｈＣＤＲ１（配列番号８６１）、ｖｈＣＤＲ２（配列番号８６２）、ｖｈＣＤＲ３（配列番号８６３）、ｖｌＣＤＲ１（配列番号８６５）、ｖｌＣＤＲ２（配列番号８６６）及びｖｌＣＤＲ３（配列番号８６７）の配列、
・図４１Ｇ（ＣＨＡ．７．５１４）のｖｈＣＤＲ１（配列番号８６９）、ｖｈＣＤＲ２（配列番号８７０）、ｖｈＣＤＲ３（配列番号８７１）、ｖｌＣＤＲ１（配列番号８７３）、ｖｌＣＤＲ２（配列番号８７４）及びｖｌＣＤＲ３（配列番号８７５）の配列、
・図４１Ｈ（ＣＨＡ．７．５１６）のｖｈＣＤＲ１（配列番号８７７）、ｖｈＣＤＲ２（配列番号８７８）、ｖｈＣＤＲ３（配列番号８７９）、ｖｌＣＤＲ１（配列番号８８１）、ｖｌＣＤＲ２（配列番号８８２）及びｖｌＣＤＲ３（配列番号８８３）の配列、
・図４１Ｉ（ＣＨＡ．７．５１８）のｖｈＣＤＲ１（配列番号８８５）、ｖｈＣＤＲ２（配列番号８８６）、ｖｈＣＤＲ３（配列番号８８７）、ｖｌＣＤＲ１（配列番号８８９）、ｖｌＣＤＲ２（配列番号８９０）及びｖｌＣＤＲ３（配列番号８９１）の配列、
・図４１Ｊ（ＣＨＡ．７．５２０．１）のｖｈＣＤＲ１（配列番号８９３）、ｖｈＣＤＲ２（配列番号８９４）、ｖｈＣＤＲ３（配列番号８９５）、ｖｌＣＤＲ１（配列番号８９７）、ｖｌＣＤＲ２（配列番号８９８）及びｖｌＣＤＲ３（配列番号８９９）の配列、
・図４１Ｋ（ＣＨＡ．７．５２０．２）のｖｈＣＤＲ１（配列番号９０１）、ｖｈＣＤＲ２（配列番号９０２）、ｖｈＣＤＲ３（配列番号９０３）、ｖｌＣＤＲ１（配列番号９０５）、ｖｌＣＤＲ２（配列番号９０６）及びｖｌＣＤＲ３（配列番号９０７）の配列、
・図４１Ｌ（ＣＨＡ．７．５２２）のｖｈＣＤＲ１（配列番号９０９）、ｖｈＣＤＲ２（配列番号９１０）、ｖｈＣＤＲ３（配列番号９１１）、ｖｌＣＤＲ１（配列番号９１３）、ｖｌＣＤＲ２（配列番号９１４）及びｖｌＣＤＲ３（配列番号９１５）の配列、
・図４１Ｍ（ＣＨＡ．７．５２４）のｖｈＣＤＲ１（配列番号９１７）、ｖｈＣＤＲ２（配列番号９１８）、ｖｈＣＤＲ３（配列番号９１９）、ｖｌＣＤＲ１（配列番号９２１）、ｖｌＣＤＲ２（配列番号９２２）及びｖｌＣＤＲ３（配列番号９２３）の配列、
・図４１Ｎ（ＣＨＡ．７．５２６）のｖｈＣＤＲ１（配列番号９２５）、ｖｈＣＤＲ２（配列番号９２６）、ｖｈＣＤＲ３（配列番号９２７）、ｖｌＣＤＲ１（配列番号９２９）、ｖｌＣＤＲ２（配列番号９３０）及びｖｌＣＤＲ３（配列番号９３１）の配列、
・図４１Ｏ（ＣＨＡ．７．５２７）のｖｈＣＤＲ１（配列番号９３３）、ｖｈＣＤＲ２（配列番号９３４）、ｖｈＣＤＲ３（配列番号９３５）、ｖｌＣＤＲ１（配列番号９３７）、ｖｌＣＤＲ２（配列番号９３８）及びｖｌＣＤＲ３（配列番号９３９）の配列、
・図４１Ｐ（ＣＨＡ．７．５２８）のｖｈＣＤＲ１（配列番号９４１）、ｖｈＣＤＲ２（配列番号９４２）、ｖｈＣＤＲ３（配列番号９４３）、ｖｌＣＤＲ１（配列番号９４５）、ｖｌＣＤＲ２（配列番号９４６）及びｖｌＣＤＲ３（配列番号９４７）の配列、
・図４１Ｑ（ＣＨＡ．７．５３０）のｖｈＣＤＲ１（配列番号９４９）、ｖｈＣＤＲ２（配列番号９５０）、ｖｈＣＤＲ３（配列番号９５１）、ｖｌＣＤＲ１（配列番号９５３）、ｖｌＣＤＲ２（配列番号９５４）及びｖｌＣＤＲ３（配列番号９５５）の配列、
・図４１Ｒ（ＣＨＡ．７．５３４）のｖｈＣＤＲ１（配列番号９５７）、ｖｈＣＤＲ２（配列番号９５８）、ｖｈＣＤＲ３（配列番号９５９）、ｖｌＣＤＲ１（配列番号９６１）、ｖｌＣＤＲ２（配列番号９６２）及びｖｌＣＤＲ３（配列番号９６３）の配列、
・図４１Ｓ（ＣＨＡ．７．５３５）のｖｈＣＤＲ１（配列番号９６５）、ｖｈＣＤＲ２（配列番号９６６）、ｖｈＣＤＲ３（配列番号９６７）、ｖｌＣＤＲ１（配列番号９６９）、ｖｌＣＤＲ２（配列番号９７０）及びｖｌＣＤＲ３（配列番号９７１）の配列、
・図４１Ｔ（ＣＨＡ．７．５３７）のｖｈＣＤＲ１（配列番号９７３）、ｖｈＣＤＲ２（配列番号９７４）、ｖｈＣＤＲ３（配列番号９７５）、ｖｌＣＤＲ１（配列番号９７７）、ｖｌＣＤＲ２（配列番号９７８）及びｖｌＣＤＲ３（配列番号９７９）の配列、
・図４１Ｕ（ＣＨＡ．７．５３８．１）のｖｈＣＤＲ１（配列番号９８１）、ｖｈＣＤＲ２（配列番号９８２）、ｖｈＣＤＲ３（配列番号９８３）、ｖｌＣＤＲ１（配列番号９８５）、ｖｌＣＤＲ２（配列番号９８６）及びｖｌＣＤＲ３（配列番号９８７）の配列、
・図４１Ｖ（ＣＨＡ．７．５３８．２）のｖｈＣＤＲ１（配列番号９８９）、ｖｈＣＤＲ２（配列番号９９０）、ｖｈＣＤＲ３（配列番号９９１）、ｖｌＣＤＲ１（配列番号９９３）、ｖｌＣＤＲ２（配列番号９９４）及びｖｌＣＤＲ３（配列番号９９５）の配列、
・図４１Ｗ（ＣＨＡ．７．５４３）のｖｈＣＤＲ１（配列番号９９７）、ｖｈＣＤＲ２（配列番号９９８）、ｖｈＣＤＲ３（配列番号９９９）、ｖｌＣＤＲ１（配列番号１００１）、ｖｌＣＤＲ２（配列番号１００２）及びｖｌＣＤＲ３（配列番号１００３）の配列、
・図４１Ｘ（ＣＨＡ．７．５４４）のｖｈＣＤＲ１（配列番号１００５）、ｖｈＣＤＲ２（配列番号１００６）、ｖｈＣＤＲ３（配列番号１００７）、ｖｌＣＤＲ１（配列番号１００９）、ｖｌＣＤＲ２（配列番号１０１０）及びｖｌＣＤＲ３（配列番号１０１１）の配列、
・図４１Ｙ（ＣＨＡ．７．５４５）のｖｈＣＤＲ１（配列番号１０１３）、ｖｈＣＤＲ２（配列番号１０１４）、ｖｈＣＤＲ３（配列番号１０１５）、ｖｌＣＤＲ１（配列番号１０１７）、ｖｌＣＤＲ２（配列番号１０１８）及びｖｌＣＤＲ３（配列番号１０１９）の配列、
・図４１Ｚ（ＣＨＡ．７．５４６）のｖｈＣＤＲ１（配列番号１０２１）、ｖｈＣＤＲ２（配列番号１０２２）、ｖｈＣＤＲ３（配列番号１０２３）、ｖｌＣＤＲ１（配列番号１０２５）、ｖｌＣＤＲ２（配列番号１０２６）及びｖｌＣＤＲ３（配列番号１０２７）の配列、
・図４１ＡＡ（ＣＨＡ．７．５４７）のｖｈＣＤＲ１（配列番号１０２９）、ｖｈＣＤＲ２（配列番号１０３０）、ｖｈＣＤＲ３（配列番号１０３１）、ｖｌＣＤＲ１（配列番号１０３３）、ｖｌＣＤＲ２（配列番号１０３４）及びｖｌＣＤＲ３（配列番号１０３５）の配列、
・図４１ＢＢ（ＣＨＡ．７．５４８）のｖｈＣＤＲ１（配列番号１０３７）、ｖｈＣＤＲ２（配列番号１０３８）、ｖｈＣＤＲ３（配列番号１０３９）、ｖｌＣＤＲ１（配列番号１０４１）、ｖｌＣＤＲ２（配列番号１０４２）及びｖｌＣＤＲ３（配列番号１０４３）の配列、
・図４１ＣＣ（ＣＨＡ．７．５４９）のｖｈＣＤＲ１（配列番号１０４５）、ｖｈＣＤＲ２（配列番号１０４６）、ｖｈＣＤＲ３（配列番号１０４７）、ｖｌＣＤＲ１（配列番号１０４９）、ｖｌＣＤＲ２（配列番号１０５０）及びｖｌＣＤＲ３（配列番号１０５１）の配列、並びに
・図４１ＤＤ（ＣＨＡ．７．５５０）のｖｈＣＤＲ１（配列番号１０５３）、ｖｈＣＤＲ２（配列番号１０５４）、ｖｈＣＤＲ３（配列番号１０５５）、ｖｌＣＤＲ１（配列番号１０５７）、ｖｌＣＤＲ２（配列番号１０５８）及びｖｌＣＤＲ３（配列番号１０５９）の配列、
から成る群から選択されるｖｈＣＤＲ１、ｖｈＣＤＲ２、ｖｈＣＤＲ３、ｖｌＣＤＲ１、ｖｌＣＤＲ２及びｖｌＣＤＲ３を含む、請求項１に記載の使用のための抗ＰＶＲＩＧ抗体組成物。 - 前記抗体が、図４１Ｉの可変重鎖ドメイン（配列番号８８４）及び可変軽鎖ドメイン（配列番号８８８）を含む、請求項１又は２に記載の使用のための抗ＰＶＲＩＧ抗体組成物。
- 前記抗体が、図４１Ｕの可変重鎖ドメイン（配列番号８８４）及び可変軽鎖ドメイン（配列番号８８８）を含む、請求項１又は２に記載の使用のための抗ＰＶＲＩＧ抗体組成物。
- 前記抗体が免疫刺激抗体、サイトカイン療法、免疫調節薬物と併用するためのものである、請求項１〜４のいずれか１項に記載の使用のための抗ＰＶＲＩＧ抗体組成物。
- 患者のＴ細胞を活性化することによる癌の治療における使用のための、抗ＰＶＲＩＧ抗体組成物であって、前記抗体が、
ｉ）配列番号１４３４の重鎖可変ドメインと、
ｉｉ）配列番号１４５３の軽鎖可変ドメインとを含む、抗ＰＶＲＩＧ抗体組成物。 - 患者のＴ細胞を活性化することによる癌の治療における使用のための、抗ＰＶＲＩＧ抗体組成物であって、前記抗体が、
ｉ）配列番号１４４７の重鎖可変ドメインと、
ｉｉ）配列番号１４６２の軽鎖可変ドメインとを含む、抗ＰＶＲＩＧ抗体組成物。 - 前記Ｔ細胞が細胞傷害性Ｔ細胞（ＣＴＬ）である、請求項６又は７に記載の使用のための抗ＰＶＲＩＧ抗体組成物。
- 前記Ｔ細胞がＣＤ４＋Ｔ細胞、ＣＤ８＋Ｔ細胞から成る群から選択される、請求項６又は７に記載の使用のための抗ＰＶＲＩＧ抗体組成物。
- 前記活性化がインターフェロン−γ産生の増加及び／又は炎症促進性サイトカイン分泌の増加として測定される、請求項６〜９のいずれか１項に記載の使用のための抗ＰＶＲＩＧ抗体組成物。
- 前記癌が、前立腺癌、肝臓癌（ＨＣＣ）、結腸直腸癌、卵巣癌、子宮内膜癌、乳癌、膵臓癌、胃癌、子宮頚癌、頭頚部癌、甲状腺癌、精巣癌、尿路上皮癌、肺癌、黒色腫、非黒色腫皮膚癌（扁平細胞及び基底細胞癌）、神経膠腫、腎臓癌（ＲＣＣ）、リンパ腫（ＮＨＬまたはＨＬ）、急性骨髄性白血病（ＡＭＬ）、）、Ｔ細胞急性リンパ芽球性白血病（Ｔ−ＡＬＬ）、びまん性大細胞型Ｂ細胞リンパ腫、精巣胚細胞腫瘍、中皮腫及び食道癌からなる群から選択される、請求項６〜１０のいずれか１項に記載の使用のための抗ＰＶＲＩＧ抗体組成物。
- ｉ）配列番号１４３４の重鎖可変ドメインと、
ｉｉ）配列番号１４５３の軽鎖可変ドメインとを含む、抗ＰＶＲＩＧ抗体。 - 核酸組成物であって、
ａ）配列番号１４３４の重鎖可変ドメインをコードする第１の核酸と、
ｂ）配列番号１４５３の軽鎖可変ドメインをコードする第２の核酸と、を含む、核酸組成物。 - 発現ベクター組成物であって、
ａ）請求項１３に記載の前記第１の核酸を含む第１の発現ベクターと、
ｂ）請求項１３に記載の前記第２の核酸を含む第２の発現ベクターと、を含む、発現ベクター組成物。 - 請求項１３に記載の前記第１の核酸と、請求項１３に記載の前記第２の核酸と、を含む発現ベクターを含む、発現ベクター組成物。
- 請求項１４または１５に記載の発現ベクター組成物を含む、宿主細胞。
- 抗ＰＶＲＩＧ抗体を作製する方法であって、
ａ）請求項１６に記載の宿主細胞を、前記抗体が発現される条件下で培養することと、
ｂ）前記抗体を回収することと、を含む、方法。 - ｉ）配列番号１４４７の重鎖可変ドメインと、
ｉｉ）配列番号１４６２の軽鎖可変ドメインとを含む、抗ＰＶＲＩＧ抗体。 - 核酸組成物であって、
ａ）配列番号１４４７の重鎖可変ドメインをコードする第１の核酸と、
ｂ）配列番号１４６２の軽鎖可変ドメインをコードする第２の核酸と、を含む、核酸組成物。 - 発現ベクター組成物であって、
ａ）請求項１９に記載の前記第１の核酸を含む第１の発現ベクターと、
ｂ）請求項１９に記載の前記第２の核酸を含む第２の発現ベクターと、を含む、発現ベクター組成物。 - 請求項１９に記載の前記第１の核酸と、請求項１９に記載の前記第２の核酸と、を含む発現ベクターを含む、発現ベクター組成物。
- 請求項２０または２１に記載の発現ベクター組成物を含む、宿主細胞。
- 抗ＰＶＲＩＧ抗体を作製する方法であって、
ａ）請求項２２に記載の宿主細胞を、前記抗体が発現される条件下で培養することと、
ｂ）前記抗体を回収することと、を含む、方法。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022067066A JP2022106783A (ja) | 2015-02-19 | 2022-04-14 | 抗ｐｖｒｉｇ抗体及び使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118208P | 2015-02-19 | 2015-02-19 | |
| US62/118,208 | 2015-02-19 | ||
| US201562141120P | 2015-03-31 | 2015-03-31 | |
| US62/141,120 | 2015-03-31 | ||
| US201562235823P | 2015-10-01 | 2015-10-01 | |
| US62/235,823 | 2015-10-01 | ||
| PCT/US2016/018809 WO2016134333A1 (en) | 2015-02-19 | 2016-02-19 | Anti-pvrig antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022067066A Division JP2022106783A (ja) | 2015-02-19 | 2022-04-14 | 抗ｐｖｒｉｇ抗体及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512443A JP2018512443A (ja) | 2018-05-17 |
| JP2018512443A5 true JP2018512443A5 (ja) | 2019-07-04 |
| JP7115856B2 JP7115856B2 (ja) | 2022-08-09 |
Family
ID=55453315
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562952A Active JP7115856B2 (ja) | 2015-02-19 | 2016-02-19 | 抗ｐｖｒｉｇ抗体及び使用方法 |
| JP2022067066A Pending JP2022106783A (ja) | 2015-02-19 | 2022-04-14 | 抗ｐｖｒｉｇ抗体及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022067066A Pending JP2022106783A (ja) | 2015-02-19 | 2022-04-14 | 抗ｐｖｒｉｇ抗体及び使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (7) | US10227408B2 (ja) |
| EP (4) | EP3295951B1 (ja) |
| JP (2) | JP7115856B2 (ja) |
| CN (2) | CN115350275A (ja) |
| AU (3) | AU2016219835B2 (ja) |
| CA (1) | CA2976926A1 (ja) |
| CY (2) | CY1122970T1 (ja) |
| DK (3) | DK3653221T3 (ja) |
| ES (3) | ES2929293T3 (ja) |
| HK (2) | HK1247568A1 (ja) |
| HR (3) | HRP20221284T1 (ja) |
| HU (3) | HUE049032T2 (ja) |
| IL (2) | IL254039B2 (ja) |
| LT (3) | LT3258951T (ja) |
| MX (2) | MX2017010667A (ja) |
| PL (3) | PL3258951T3 (ja) |
| PT (3) | PT3295951T (ja) |
| RU (2) | RU2020128686A (ja) |
| SG (1) | SG11201706583PA (ja) |
| SI (2) | SI3258951T1 (ja) |
| WO (1) | WO2016134333A1 (ja) |
| ZA (1) | ZA201706323B (ja) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130058957A1 (en) * | 2010-02-23 | 2013-03-07 | The University Of Tokyo | Dendritic cell immunoreceptor agonist |
| WO2015095895A1 (en) | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
| EP3259597B1 (en) | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
| DK3653221T3 (da) | 2015-02-19 | 2022-10-24 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| EP3288570A4 (en) | 2015-04-29 | 2018-11-21 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| US11078278B2 (en) * | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| JP2018525999A (ja) * | 2015-08-28 | 2018-09-13 | アレクトル エルエルシー | 抗Ｓｉｇｌｅｃ−７抗体及びその使用方法 |
| EP4223784A3 (en) * | 2015-09-02 | 2023-10-04 | The Regents of the University of Colorado, a body corporate | Compositions and methods for modulating t-cell mediated immune response |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| KR102450208B1 (ko) * | 2016-08-17 | 2022-10-05 | 컴퓨젠 엘티디. | 항-tigit 항체, 항-pvrig 항체 및 이들의 조합 |
| CA3035075A1 (en) | 2016-09-23 | 2018-03-29 | Fred Hutchinson Cancer Research Center | Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof |
| EA201992131A1 (ru) | 2017-03-15 | 2020-02-06 | Фред Хатчинсон Кэнсер Рисерч Сентер | Высокоаффинные специфичные к mage-a1 tcr и их применение |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELINE BINDING PROTEINS |
| CN110891567B (zh) | 2017-05-24 | 2024-01-09 | 效应治疗股份有限公司 | 用于改善的抗肿瘤免疫应答的组合物和方法 |
| CA3064331A1 (en) | 2017-06-01 | 2018-12-06 | Compugen Ltd. | Triple combination antibody therapies |
| MX2020000595A (es) | 2017-07-17 | 2020-09-10 | Janssen Biotech Inc | Regiones de unión al antígeno contra dominios de fibronectina tipo iii y métodos para su uso. |
| CA3071661A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | Strep-tag specific chimeric receptors and uses thereof |
| AU2018327229A1 (en) | 2017-09-06 | 2020-02-27 | Fred Hutchinson Cancer Center | Strep-tag specific binding proteins and uses thereof |
| EP3678690A1 (en) | 2017-09-06 | 2020-07-15 | Fred Hutchinson Cancer Research Center | Methods for improving adoptive cell therapy |
| BR112020007249B1 (pt) | 2017-10-13 | 2022-11-22 | Harpoon Therapeutics, Inc | Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas |
| WO2019109047A1 (en) | 2017-12-01 | 2019-06-06 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
| WO2019140278A1 (en) | 2018-01-11 | 2019-07-18 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting core binding factor antigens |
| US10752691B2 (en) | 2018-03-13 | 2020-08-25 | Tusk Therapeutics Ltd. | Anti-CD25 antibody agents |
| AU2019278875A1 (en) | 2018-05-31 | 2020-10-22 | Glyconex Inc. | Therapeutic antibodies binding to biantennary Lewis B and Lewis Y antigens |
| CA3101019A1 (en) | 2018-06-01 | 2019-12-05 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
| US11279758B2 (en) * | 2018-07-20 | 2022-03-22 | Surface Oncology, Inc. | Anti-CD112R compositions and methods |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| JP2021534752A (ja) | 2018-08-22 | 2021-12-16 | フレッド ハッチンソン キャンサー リサーチ センター | Ｋｒａｓ抗原またはｈｅｒ２抗原を標的とする免疫療法 |
| WO2020041541A2 (en) | 2018-08-23 | 2020-02-27 | Seattle Genetics, Inc. | Anti-tigit antibodies |
| WO2020056393A1 (en) * | 2018-09-14 | 2020-03-19 | Kindred Biosciences, Inc. | Anti-il4 receptor antibodies for veterinary use |
| WO2020068702A1 (en) | 2018-09-24 | 2020-04-02 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
| AU2019346466A1 (en) | 2018-09-25 | 2021-05-20 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| KR20210102231A (ko) | 2018-11-09 | 2021-08-19 | 프레드 헛친슨 켄서 리서치 센터 | 메소텔린에 특이적인 t 세포 수용체 및 면역요법에서의 그의 용도 |
| CN113544148B (zh) | 2018-12-19 | 2024-04-05 | 胡默波斯生物医学公司 | 中和乙型肝炎病毒的抗体和其用途 |
| AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| PE20212269A1 (es) * | 2019-02-06 | 2021-11-30 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem1 y metodos relacionados |
| US10836828B2 (en) | 2019-02-06 | 2020-11-17 | Pionyr Immunotherapeutics, Inc. | Anti-TREM1 antibodies and related methods |
| JP2022521513A (ja) | 2019-02-20 | 2022-04-08 | フレッド ハッチンソン キャンサー リサーチ センター | Ｒａｓネオ抗原に特異的な結合タンパク質およびその使用 |
| BR112021017703A8 (pt) | 2019-03-11 | 2023-04-18 | Hutchinson Fred Cancer Res | Receptores de células t wt1 de alta avidez e usos dos mesmos |
| BR112022001575A2 (pt) | 2019-07-29 | 2022-04-19 | Compugen Ltd | Formulações de anticorpos anti-pvrig e usos dos mesmos |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| EP4017872A1 (en) | 2019-08-20 | 2022-06-29 | Fred Hutchinson Cancer Center | T-cell immunotherapy specific for wt-1 |
| CA3152511A1 (en) | 2019-08-29 | 2021-03-04 | Vir Biotechnology, Inc. | Antibody compositions and methods for treating hepatitis b virus infection |
| EP4054632A1 (en) | 2019-11-04 | 2022-09-14 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
| WO2021097294A1 (en) * | 2019-11-15 | 2021-05-20 | Surface Oncology, Inc. | Compositions and methods for immunotherapy |
| WO2021113831A1 (en) | 2019-12-05 | 2021-06-10 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| JP2023516936A (ja) | 2020-03-13 | 2023-04-21 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Ｐｖｒｉｇ結合タンパク質及びその医薬用途 |
| KR20230042023A (ko) | 2020-06-24 | 2023-03-27 | 비르 바이오테크놀로지, 인코포레이티드 | 조작된 b형 간염 바이러스 중화 항체 및 이의 용도 |
| AU2021306613A1 (en) | 2020-07-07 | 2023-02-02 | BioNTech SE | Therapeutic RNA for HPV-positive cancer |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
| JP2023542528A (ja) | 2020-09-24 | 2023-10-10 | フレッド ハッチンソン キャンサー センター | Ｓｏｘ２抗原を標的とする免疫療法 |
| TW202222841A (zh) | 2020-10-06 | 2022-06-16 | 福瑞德哈金森腫瘤研究中心 | 用於治療表現mage-a1之疾病的組成物及方法 |
| EP4232822A2 (en) * | 2020-10-26 | 2023-08-30 | Compugen Ltd. | Pvrl2 and/or pvrig as biomarkers for treatment |
| CN112433055A (zh) * | 2020-11-04 | 2021-03-02 | 上海药明生物技术有限公司 | 一种基于报告基因方法检测pvrig抗体的生物学活性的方法 |
| WO2022132836A2 (en) | 2020-12-14 | 2022-06-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| EP4284428A1 (en) | 2021-01-26 | 2023-12-06 | VIR Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus infection |
| EP4284516A1 (en) | 2021-01-28 | 2023-12-06 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
| US20240076373A1 (en) * | 2021-01-28 | 2024-03-07 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
| CA3207791A1 (en) * | 2021-02-09 | 2022-08-18 | Shanghai Junshi Biosciences Co., Ltd. | Anti-cd112r antibody and use thereof |
| CA3206413A1 (en) | 2021-02-11 | 2022-08-18 | Pinchas TSUKERMAN | Antibodies against cd112r and uses thereof |
| CN115925917A (zh) * | 2021-03-08 | 2023-04-07 | 合肥天港免疫药物有限公司 | 抗pvrig蛋白抗体或抗体片段及其用途 |
| EP4314060A1 (en) | 2021-03-31 | 2024-02-07 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
| WO2022258049A1 (en) * | 2021-06-10 | 2022-12-15 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric pvrig |
| WO2023275621A1 (en) * | 2021-07-01 | 2023-01-05 | Compugen Ltd. | Anti-tigit and anti-pvrig in monotherapy and combination treatments |
| IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
| TW202317602A (zh) | 2021-07-15 | 2023-05-01 | 福瑞德哈金森腫瘤中心 | 嵌合多肽 |
| EP4378954A1 (en) | 2021-07-30 | 2024-06-05 | Shandong Simcere Biopharmaceutical Co., Ltd. | Anti-pvrig/anti-tigit bispecific antibody and application |
| TW202328195A (zh) | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｐｄ－１的蛋白及其醫藥用途 |
| WO2023040940A1 (zh) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 |
| TW202317644A (zh) | 2021-09-15 | 2023-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種含抗ｐｖｒｉｇ／ｔｉｇｉｔ雙特異性抗體的醫藥組成物 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023064958A1 (en) | 2021-10-15 | 2023-04-20 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
| WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| US20240103010A1 (en) | 2022-03-18 | 2024-03-28 | Compugen Ltd. | Pvrl2 and/or pvrig as biomarkers for treatment |
| CN116925233A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 |
| CN116925222A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗pvrig抗体、其药物组合物及用途 |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2023230439A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
| US20240109965A1 (en) * | 2022-06-14 | 2024-04-04 | Ablynx N.V. | Immunoglobulin single variable domains targeting t cell receptor |
| WO2024026496A1 (en) | 2022-07-28 | 2024-02-01 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
| WO2024032700A1 (en) * | 2022-08-10 | 2024-02-15 | Beigene, Ltd. | Anti-pvrig antibodies and methods of use |
| WO2024046245A1 (zh) * | 2022-08-31 | 2024-03-07 | 石药集团巨石生物制药有限公司 | 抗pvrig抗体及其应用 |
| WO2024098980A1 (en) * | 2022-11-10 | 2024-05-16 | Huahui Health Ltd. | Anti-cd112r antibodies and use thereof |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| AU690528B2 (en) | 1992-12-04 | 1998-04-30 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US20040002117A1 (en) | 1998-02-12 | 2004-01-01 | Hogan Patrick G. | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2359067C (en) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2000052151A2 (en) | 1999-03-05 | 2000-09-08 | Incyte Pharmaceuticals, Inc. | Human secretory proteins |
| EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US20030224379A1 (en) | 2000-01-21 | 2003-12-04 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| AU2002305539A1 (en) | 2001-05-09 | 2002-11-18 | Yale University | Toll/interleukin-1 receptor adaptor protein (tirap) |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| MXPA04009924A (es) | 2002-04-09 | 2005-07-01 | Kyowa Hakko Kogyo Kk | Celulas de genoma modificado. |
| US20040121370A1 (en) | 2002-09-11 | 2004-06-24 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| EP1594447A2 (en) | 2002-10-02 | 2005-11-16 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| WO2004058805A2 (en) * | 2002-12-26 | 2004-07-15 | Asahi Kasei Pharma Corporation | T cell activating gene |
| ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7622265B2 (en) | 2005-02-22 | 2009-11-24 | Genentech, Inc. | Methods and compositions for modulating prostasin |
| ES2772674T3 (es) | 2005-05-12 | 2020-07-08 | Zymogenetics Inc | Composiciones y métodos para modular respuestas inmunitarias |
| CA2648915A1 (en) | 2006-04-13 | 2007-11-01 | Zymogenetics, Inc. | Tetramerizing polypeptides and methods of use |
| WO2007121364A2 (en) | 2006-04-13 | 2007-10-25 | Zymogenetics, Inc. | Tetramerizing polypeptides and methods of use |
| US20090318376A1 (en) | 2006-06-15 | 2009-12-24 | Korea Research Institute Of Bioscience And Biotechnology | High Throughput Screening Method of Binding Inhibitor Between caspase3 and XIAP and Binding Inhibitor Screened Thereby |
| WO2008021290A2 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| CN101541834A (zh) * | 2006-10-06 | 2009-09-23 | 武田药品工业株式会社 | 癌症的预防和/或治疗剂 |
| US8344112B2 (en) * | 2007-07-31 | 2013-01-01 | Merck Sharp & Dohme Limited | IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
| US20120082659A1 (en) | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| KR101924831B1 (ko) | 2008-04-09 | 2018-12-05 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
| EP2370813A4 (en) | 2008-12-04 | 2012-05-23 | Univ California | MATERIALS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER |
| WO2010109924A1 (ja) | 2009-03-25 | 2010-09-30 | 国立大学法人東北大学 | Ｌｈ型二重特異性抗体 |
| US20110217297A1 (en) | 2010-03-03 | 2011-09-08 | Koo Foundation Sun Yat-Sen Cancer Center | Methods for classifying and treating breast cancers |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| WO2012129488A2 (en) | 2011-03-23 | 2012-09-27 | Virginia Commonwealth University | Gene signatures associated with rejection or recurrence of cancer |
| WO2012156515A1 (en) | 2011-05-18 | 2012-11-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | Molecular analysis of acute myeloid leukemia |
| US20140141996A1 (en) * | 2011-06-22 | 2014-05-22 | Oncocyte Corporation | Methods and Compositions for the Treatment and Diagnosis of Cancer |
| KR20150018604A (ko) | 2012-06-06 | 2015-02-23 | 온코메드 파마슈티칼스, 인크. | 히포 경로를 조절하는 결합제 및 그의 용도 |
| CN103073644B (zh) | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
| RS60826B1 (sr) | 2013-07-16 | 2020-10-30 | Hoffmann La Roche | Postupci lečenja kancera upotrebom antagonista vezivanja pd-1 ose i tigit inhibitora |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| IL250583B (en) | 2014-08-19 | 2022-07-01 | Merck Sharp & Dohme | Anti-tigit antibodies |
| CN113929770A (zh) | 2014-11-21 | 2022-01-14 | 百时美施贵宝公司 | 包含修饰的重链恒定区的抗体 |
| MA40662B1 (fr) | 2014-12-23 | 2020-12-31 | Bristol Myers Squibb Co | Anticorps contre tigit |
| EP3259597B1 (en) | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
| DK3653221T3 (da) | 2015-02-19 | 2022-10-24 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| US11078278B2 (en) | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| JO3620B1 (ar) * | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| EP4223784A3 (en) * | 2015-09-02 | 2023-10-04 | The Regents of the University of Colorado, a body corporate | Compositions and methods for modulating t-cell mediated immune response |
| WO2017053748A2 (en) | 2015-09-25 | 2017-03-30 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
| ES2910027T3 (es) | 2015-10-01 | 2022-05-11 | Potenza Therapeutics Inc | Proteínas de unión a antígeno anti-TIGIT y métodos de uso de las mismas |
| WO2018017864A2 (en) | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
| KR102450208B1 (ko) | 2016-08-17 | 2022-10-05 | 컴퓨젠 엘티디. | 항-tigit 항체, 항-pvrig 항체 및 이들의 조합 |
-
2016
- 2016-02-19 DK DK19214231.3T patent/DK3653221T3/da active
- 2016-02-19 LT LTEP16707603.3T patent/LT3258951T/lt unknown
- 2016-02-19 ES ES19214231T patent/ES2929293T3/es active Active
- 2016-02-19 EP EP17192325.3A patent/EP3295951B1/en active Active
- 2016-02-19 US US15/048,967 patent/US10227408B2/en active Active
- 2016-02-19 IL IL254039A patent/IL254039B2/en unknown
- 2016-02-19 PT PT171923253T patent/PT3295951T/pt unknown
- 2016-02-19 PL PL16707603T patent/PL3258951T3/pl unknown
- 2016-02-19 HU HUE16707603A patent/HUE049032T2/hu unknown
- 2016-02-19 RU RU2020128686A patent/RU2020128686A/ru unknown
- 2016-02-19 SI SI201630706T patent/SI3258951T1/sl unknown
- 2016-02-19 HU HUE17192325A patent/HUE049791T2/hu unknown
- 2016-02-19 JP JP2017562952A patent/JP7115856B2/ja active Active
- 2016-02-19 MX MX2017010667A patent/MX2017010667A/es active IP Right Grant
- 2016-02-19 CN CN202210521528.8A patent/CN115350275A/zh active Pending
- 2016-02-19 SG SG11201706583PA patent/SG11201706583PA/en unknown
- 2016-02-19 HU HUE19214231A patent/HUE061084T2/hu unknown
- 2016-02-19 LT LTEP17192325.3T patent/LT3295951T/lt unknown
- 2016-02-19 RU RU2017132214A patent/RU2732042C2/ru active
- 2016-02-19 EP EP16707603.3A patent/EP3258951B1/en active Active
- 2016-02-19 PL PL19214231.3T patent/PL3653221T3/pl unknown
- 2016-02-19 EP EP19214231.3A patent/EP3653221B1/en active Active
- 2016-02-19 CN CN201680023677.4A patent/CN107580500B/zh active Active
- 2016-02-19 PT PT167076033T patent/PT3258951T/pt unknown
- 2016-02-19 SI SI201630837T patent/SI3295951T1/sl unknown
- 2016-02-19 AU AU2016219835A patent/AU2016219835B2/en active Active
- 2016-02-19 WO PCT/US2016/018809 patent/WO2016134333A1/en active Application Filing
- 2016-02-19 EP EP22180817.3A patent/EP4129320A1/en active Pending
- 2016-02-19 LT LTEP19214231.3T patent/LT3653221T/lt unknown
- 2016-02-19 PT PT192142313T patent/PT3653221T/pt unknown
- 2016-02-19 DK DK17192325.3T patent/DK3295951T3/da active
- 2016-02-19 ES ES17192325T patent/ES2806800T3/es active Active
- 2016-02-19 DK DK16707603.3T patent/DK3258951T3/da active
- 2016-02-19 PL PL17192325T patent/PL3295951T3/pl unknown
- 2016-02-19 ES ES16707603T patent/ES2786651T3/es active Active
- 2016-02-19 HR HRP20221284TT patent/HRP20221284T1/hr unknown
- 2016-02-19 CA CA2976926A patent/CA2976926A1/en active Pending
- 2016-09-27 US US15/277,980 patent/US11220542B2/en active Active
- 2016-09-27 US US15/277,978 patent/US9714289B2/en active Active
-
2017
- 2017-08-18 MX MX2020009461A patent/MX2020009461A/es unknown
- 2017-09-19 ZA ZA2017/06323A patent/ZA201706323B/en unknown
-
2018
- 2018-02-13 US US15/896,040 patent/US10351625B2/en active Active
- 2018-05-31 HK HK18107128.0A patent/HK1247568A1/zh unknown
- 2018-05-31 HK HK18107129.9A patent/HK1247569A1/zh unknown
-
2020
- 2020-01-21 US US16/748,695 patent/US11623955B2/en active Active
- 2020-04-09 HR HRP20200572TT patent/HRP20200572T1/hr unknown
- 2020-04-27 CY CY20201100381T patent/CY1122970T1/el unknown
- 2020-06-17 US US16/904,510 patent/US11795220B2/en active Active
- 2020-07-07 HR HRP20201066TT patent/HRP20201066T1/hr unknown
- 2020-07-21 CY CY20201100669T patent/CY1123259T1/el unknown
- 2020-11-05 AU AU2020264349A patent/AU2020264349B2/en active Active
-
2022
- 2022-04-14 JP JP2022067066A patent/JP2022106783A/ja active Pending
-
2023
- 2023-06-28 IL IL304117A patent/IL304117A/en unknown
- 2023-08-11 US US18/448,870 patent/US20240101669A1/en active Pending
-
2024
- 2024-04-11 AU AU2024202336A patent/AU2024202336A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512443A5 (ja) | ||
| HRP20201066T1 (hr) | Anti-pvrig antitijela i postupci uporabe | |
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| HRP20201600T1 (hr) | Anti-pd-1 antitijelo i njegova uporaba | |
| MX2023000818A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
| EP4289484A3 (en) | Anti-ctla-4 antibodies and methods of use thereof | |
| JP2016527273A5 (ja) | ||
| MX2023006380A (es) | Anticuerpos anti-bcma unicamente de cadena pesada. | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| AU2018282038A1 (en) | Anti TRBC1 antigen binding domains | |
| HRP20221141T1 (hr) | Anti-lag3 protutijela | |
| WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| AU2018291128A1 (en) | Anti-B-cell maturation antigen chimeric antigen receptors with human domains | |
| HRP20160212T1 (hr) | Antitijela za terapiju kancera koji eksprimira klaudin 6 | |
| RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
| JP2019533989A5 (ja) | 抗ｐｄ−１抗体及びその使用 | |
| IL291926B1 (en) | FGFR2 inhibitors alone or in combination with immunostimulating agents in cancer treatment | |
| JP2017510661A5 (ja) | ||
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| WO2018237037A3 (en) | HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA | |
| MX2020012426A (es) | Anticuerpos anti-cd38. | |
| WO2015130732A3 (en) | Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia | |
| MX353813B (es) | Moleculas de union a vegf. | |
| PH12014502179B1 (en) | Ang2-binding molecules | |
| JP2016116527A5 (ja) |